Search results

532 results

Sorted by Relevance . Sort by Date

Guidance Remove Guidance filter
In development Remove In development filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Medical technologies guidance Remove Medical technologies guidance filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Diagnostics guidance Remove Diagnostics guidance filter
Safe staffing guidelines Remove Safe staffing guidelines filter
Quality standards Remove Quality standards filter

Pembrolizumab in combination for untreated, locally recurrent inoperable or metastatic, triple negative breast cancer [ID1546]

In development [GID-TA10417] Expected publication date: 15 September 2021

Type

Technology appraisal guidance

Status

In development
Erenumab for preventing migraine [ID1188]

In development [GID-TA10302] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Anakinra for treating active Stills disease [ID1463]

In development [GID-TA10392] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Management and organisational approaches to safe staffing

In development [GID-SGWAVE0761] Expected publication date: TBC

Type

Safe staffing guideline

Status

In development
Accident and emergency departments

In development [GID-SGWAVE0762] Expected publication date: TBC

Type

Safe staffing guideline

Status

In development
Inpatient mental health settings

In development [GID-SGWAVE0701] Expected publication date: TBC

Type

Safe staffing guideline

Status

In development
Community nursing care settings

In development [GID-SGWAVE0700] Expected publication date: TBC

Type

Safe staffing guideline

Status

In development
Mental health community settings

In development [GID-SGWAVE0702] Expected publication date: TBC

Type

Safe staffing guideline

Status

In development
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

In development [GID-HST10004] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

In development [GID-HST10007] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Multiple myeloma and related disorders - Freelite assays (and alternative technologies identified during scoping) for diagnosis in primary care

In development [GID-DT28] Expected publication date: TBC

Type

Diagnostics guidance

Status

In development
Xpert MTB/RIF assay for the detection of active pulmonary tuberculosis and multi-drug resistant tuberculosis

In development [GID-DT9] Expected publication date: TBC

Type

Diagnostics guidance

Status

In development
KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)

In development [GID-DT14] Expected publication date: TBC

Type

Diagnostics guidance

Status

In development
The Assurance Nasal Alar SpO2 Sensor (discontinued)

In development [GID-MT510] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)

In development [GID-MT517] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
DHT pilot: DECODE decision support system for the identification of dementia (Discontinued)

In development [GID-MT536] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
SeQuent Please Neo balloon catheter for in-stent coronary restenosis - update of MTG1 (discontinued)

In development [GID-MT516] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
OraQuick® HCV Rapid Antibody Test (discontinued)

In development [GID-MT117] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Levitronix CentriMag for treatment of refractory cardiogenic shock or severe cardiopulmonary insufficiency (discontinued)

In development [GID-MT130] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Clinitek Microalbumin 9 reagent strips for the early detection and monitoring of kidney disease (discontinued)

In development [GID-MT163] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Microthane implants for breast reconstruction or breast augmentation (discontinued)

In development [GID-MT267] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
SILK artery reconstruction device (discontinued)

In development [GID-MT81] Expected publication date: TBC

Type

Medical technologies guidance

Status

In development
Multiple sclerosis - sativex [ID387]

In development [GID-TAG368] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545

In development [GID-TA10418] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Prostate cancer (prevention) - dutasteride [ID75]

In development [GID-TAG409] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]

In development [GID-TAG411] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Obesity - lorcaserin [ID337]

In development [GID-TAG420] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Dementia (non-Alzheimer) - new pharmaceutical treatments [ID380]

In development [GID-TAG369] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies ID1455

In development [GID-TA10356] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]

In development [GID-TAG393] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Hypercholesterolemia - mipomersen [ID524]

In development [GID-TAG437] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Breast cancer (advanced or metastatic) - lapatinib [ID20]

In development [GID-TAG387] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]

In development [GID-TAG433] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Thrombophilia [ID393]

In development [GID-TAG374] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Systemic lupus erythematosus - prasterone [ID392]

In development [GID-TAG373] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Falls - faller's clinics [ID103]

In development [GID-TAG375] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Breast cancer (ErbB2 HER2, metastatic) - lapatinib (with paclitaxel, 1st line) [ID517]

In development [GID-TAG436] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lung cancer (non-small-cell) - cetuximab [ID9]

In development [GID-TAG395] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Venous thromboembolism (prevention) - rivaroxaban [ID463]

In development [GID-TAG427] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Multiple sclerosis (relapsing-remitting) - laquinimod [ID560]

In development [GID-TAG337] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Heart failure (acute) - serelaxin [ID673]

In development [GID-TAG454] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564]

In development [GID-TAG332] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Macular oedema (diabetic) - pegaptanib sodium [ID452]

In development [GID-TAG280] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Venous thromboembolism - apixaban (acute medical illness) [ID310]

In development [GID-TAG419] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]

In development [GID-TAG417] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Breast cancer (advanced or metastatic) hormone-sensitive - lapatinib [ID115]

In development [GID-TAG404] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lung cancer (non-small-cell, untreated) - paclitaxel formulated as albumin-bound nanoparticles (with carboplatin) [ID553]

In development [GID-TAG528] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Juvenile idiopathic arthritis - abatacept [ID27]

In development [GID-TAG402] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Glioblastoma - bevacizumab [ID80]

In development [GID-TAG413] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) ID622

In development [GID-TAG360] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development